Sunday, September 12, 2021 2:31:55 AM
A veterinarian with more than 30 years of experience in animal health pharmaceutical development, Eagleson is currently Vice President of Clinical and Regulatory Affairs at Nexvet Biopharma, a veterinary biotherapeutics company. She concurrently serves, since January 2013, as owner of Bleecker Street Consulting, an animal health consulting firm that specializes in pharmaceutical development strategy in North America, Europe and the Oceania markets. From September 2007 through December 2012, Eagleson held various leadership positions with Argenta, a pharmaceutical contract research and contract manufacturing organization. She joined Argenta as Head of Clinical Research and Development and elevated to Head of Growth Strategies where she assumed overall ownership of the company strategic plan. Prior to that, Eagleson served in several senior director roles with Pfizer, Inc. from December 1999 through February 2007, leaving the company as Senior Director of Asian Business Development where she was based in India and responsible for strategic planning and execution of Asian business initiatives for both animal health and human health organizations. Before Pfizer, Eagleson was a Director with Merial from 1991 to 1997 and served as Research Veterinarian with Merck Animal Health from 1985 to 1991. She has a Master of Veterinary Science in immunology from Massey University and Bachelor of Veterinary Science from the University of Sydney. She has also authored more than 35 publications in peer reviewed journals.
Recent ZOM News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2024 10:32:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/12/2024 08:15:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/07/2024 07:54:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:17:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 04:03:02 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 02/20/2024 11:12:44 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 09:16:29 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:11:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/09/2023 09:07:04 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 11/09/2023 09:06:12 PM
- Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference • GlobeNewswire Inc. • 09/21/2023 01:35:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/06/2023 12:18:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/10/2023 08:22:53 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/10/2023 08:05:49 PM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM